Neal Shore, MD, FACS

Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.

Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.

Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.

Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.

Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.

Neal Shore, MD, FACS, reviews the VISION clinical trial in prostate cancer imaging.

A look at the patient profile of a 62-year-old man presenting with reduced urinary flow and hematuria.

Neal Shore, MD, FACS, muses about the unmet needs in metastatic prostate cancer treatment and shares clinical pearls for community oncologists.

A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC.

Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.

An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.

Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).

A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.

An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.

Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.

Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.

Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.

Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.

Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.

A panel of experts review whether bone scans still have a place in prostate cancer imaging.

Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.

Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.

A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.

A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.

Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.

Authors from the OSPREY clinical trial highlight the key take-home messages from the trial outcomes.

Key opinion leaders review the OSPREY clinical trial studying PSMA PET scans for prostate cancer imaging.

Doctors present the patient profile of a 66-year-old man with high-risk localized prostate cancer.